The Ministry of Health, Labor and Welfare (MHLW) on January 11 ordered label revisions for Otsuka Pharmaceutical’s antipsychotic Abilify (aripiprazole/aripiprazole hydrate) and its generic versions, and four other APIs including Lixiana (edoxaban). In a notification, the MHLW ordered the makers…
To read the full story
Related Article
- Abilify, Lixiana and Others under PMDA Risk Review
December 12, 2017
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





